Woebot for Substance Use Disorders
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04096001|
Recruitment Status : Not yet recruiting
First Posted : September 19, 2019
Last Update Posted : September 19, 2019
Woebot Labs, Inc.
Information provided by (Responsible Party):
Woebot Labs, Inc.
Phase 1 of this study aims to develop a digitally-delivered substance use disorder program through the Woebot app-based platform (W-SUDs) and evaluate the effectiveness of, patient satisfaction with and the acceptability of W-SUDs as a substance use management tool.
|Condition or disease||Intervention/treatment|
|Substance Use Disorders||Device: Woebot-SUDs (W-SUDs)|
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Official Title:||RCT of Woebot for Substance Use Disorders Phase 1|
|Estimated Study Start Date :||January 2, 2020|
|Estimated Primary Completion Date :||March 1, 2020|
|Estimated Study Completion Date :||March 30, 2020|
- Device: Woebot-SUDs (W-SUDs)
Woebot-SUDs (W-SUDS), an artificially intelligence-powered conversational agent on a smartphone app, eliminates most current SUDs treatment barriers while simultaneously leveraging technology to enhance user experience and engagement. W-SUDs expands and refines existing SUDs treatments by adapting skills from cognitive behavioral therapy, motivational interviewing, and dialectical behavior therapy.
Primary Outcome Measures :
- The Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) [ Time Frame: Change from Baseline to Post-treatment at 12 weeks ]The AUDIT-C is a widely used 3-item self-report screen for hazardous or harmful alcohol consumption that is based off of the 10-item original AUDIT.
- The Drug Abuse Screening Test 10 (DAST-10) [ Time Frame: Change from Baseline to Post-treatment at 12 weeks ]The DAST-10 is a brief, 10-item self-report assesses consequences related to drug abuse, excluding alcohol and tobacco.
Secondary Outcome Measures :
- The Client Satisfaction Questionnaire (CSQ-8) [ Time Frame: Post-treatment at 12 weeks ]The CSQ-8 is an 8-item self-report scale measuring satisfaction with treatment.
- Usage Rating Profile Intervention Acceptability Subscale (URPI-usability subscale) [ Time Frame: Post-treatment at 12 weeks ]URPI-Acceptability Subscale is 6-item subscale from the URP Intervention Revised (URP-IR) scale. The URPI-Acceptability inquires about intervention acceptability. Responses range from 1= "slightly disagree" to 6="strongly agree". Scores are averages, with greater scores indicating greater intervention acceptability.
- Usage Rating Profile Intervention Feasibility Subscale (URPI-feasibility subscale) [ Time Frame: Post-treatment at 12 weeks ]URPI-Feasibility Subscale is 6-item subscale from the URP Intervention Revised (URP-IR) scale. The URPI-Feasibility inquires about factors that impact treatment usage (i.e., intervention quality). Responses range from 1= "slightly disagree" to 6="strongly agree". Scores are averages, with greater scores indicating greater intervention feasibility.
No Contacts or Locations Provided